News Archives
Richter announces the acquisition of Finox Holding
in News, Press Releases onRead more30 June 2016 Richter announces the acquisition of Finox Holding for a consideration of CHF190 million. Finox Holding, a…
00Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
in News, Press Releases onRead moreDUBLIN, Ireland and BUDAPEST, Hungary – 9 May 2016, — Allergan Plc (NYSE: AGN) and Gedeon Richter Plc. today announced positive…
Full Results of PEARL IV Study presented at the European Society of Gynaecological Endoscopy (ESGE) congress confirms the efficacy of ulipristal acetate 5 mg for the long term management of uterine fibroids
in Events, Press Releases onRead moreBudapest, 12 October 2015 – Gedeon Richter Plc. (“Richter”) announces results of the PEARL IV study at ESGE. PEARL IV…
European Commission approves Esmya® 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas)
in News, Press Releases onRead moreBudapest, Hungary – 28 May 2015 – Gedeon Richter Plc. (“Richter”) announces that the European Commission (EC) has granted approval…
European Commission approves Esmya® Type II variation, allowing a repeated course of 3-month treatment for uterine fibroids
in News, Press Releases onRead moreBudapest, Hungary, 27 January 2013: Gedeon Richter Plc. (“Richter”) announces that Esmya® 5 mg tablets (ulipristal acetate) is now licensed…
European Commission approves Esmya® for the pre-operative treatment of uterine fibroids (myomas)
in News, Press Releases onRead moreBudapest, Hungary – 27 February 2012 – Gedeon Richter Plc. (“Richter”) announces today that the European Commission (EC) has granted…
PEARL I and II studies published in New England Journal of Medicine confirm the efficacy of Esmya® (ulipristal acetate) for the pre-operative treatment of uterine fibroids (myomas)
in News, Press Releases onRead moreGeneva, Switzerland – 2 February 2012 – PregLem, the wholly owned subsidiary of Gedeon Richter, announces full results of PEARL…
Richter announces that PregLem, its wholly owned subsidiary, receives positive EMA/CHMP opinion for Esmya® for the pre-operative treatment of uterine fibroids (myomas)
in News, Press Releases onRead moreBudapest, Hungary – 16 December 2011 – Gedeon Richter Plc. (“Richter”) announces that the Committee for Medicinal Products for Human…
Richter and Watson Announce Exclusive License Agreement for Esmya™
in News, Press Releases onRead moreBUDAPEST, HUNGARY and MORRISTOWN, New Jersey – 16 December, 2010 — Gedeon Richter Plc. (“Richter”) and Watson Pharmaceuticals, Inc. (NYSE:…
Richter Announces the Acquisition of PregLem
in News, Press Releases onRead moreRichter announces the Acquisition of PregLem for an initial cash consideration of CHF150 million (€114 million) and further milestone payments…
Careers
A career at Preglem® is more than just a job. It gives you the opportunity to solve challenging global problems in a way that can change the world.
Contact us
In line with our corporate culture, we treat all information received with full confidentiality.